公司公告汇总：澳柯玛为控股子公司青岛澳柯玛生物医疗有限公司提供1000万元担保 截至2025年6月27日收盘，澳柯玛（600336）报收于6.84元，较上周的6.5元上涨5.23%。本周，澳柯玛6 月27日盘中最高价报6.93元。6月23日盘中最低价报6.4元。澳柯玛当前最新总市值54.58亿元，在白色家 电板块市值排名9/10，在两市A股市值排名2762/5151。 本周关注点 澳柯玛股份有限公司为控股子公司青岛澳柯玛生物医疗有限公司提供担保，担保金额为1000万元，已实 际为其提供的担保余额为1000万元，无反担保，公司对外担保未发生逾期情形。截至公告披露日，公司 及控股子公司对外提供担保总额为12.80亿元，占公司最近一期经审计净资产的52.44%。2025年6月24 日，公司与中国光大银行股份有限公司青岛分行签署了《最高额保证合同》，为生物医疗公司在2025年 6月24日至2026年6月23日期间内提供最高本金余额1000万元人民币的保证担保。生物医疗公司注册资本 5000万元，主营业务为超低温设备、科研实验用冰箱等生物医疗设备的开发、生产、销售及服务。2025 年一季度营业收入41097625.23 ...

Core Viewpoint - Artivion (AORT) reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share, representing a 50% earnings surprise [1] - The company posted revenues of $98.98 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.19% [2] Financial Performance - Artivion's earnings of $0.06 per share are unchanged from the same quarter last year, and the company has surpassed consensus EPS estimates two times over the last four quarters [1][2] - The company has topped consensus revenue estimates three times in the last four quarters, with year-ago revenues of $97.43 million [2] Stock Performance - Artivion shares have declined approximately 18.4% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current Zacks Rank for Artivion is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $108.7 million, and for the current fiscal year, it is $0.68 on revenues of $426.65 million [7] - The outlook for the Medical - Instruments industry is positive, ranking in the top 28% of over 250 Zacks industries, suggesting potential for outperformance [8]